- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.10. | FDA approves Regeneron's Libtayo for high-risk CSCC post-surgery | ||
| 08.10. | China accounts for one-fifth of global drugs in development | ||
| 08.10. | Ex-FDA chief Peter Marks joins Eli Lilly's infectious disease unit | ||
| 08.10. | MapLight's $251m IPO sees schizophrenia drug developers on top | ||
| 08.10. | Affinia raises $40m for gene therapy development | ||
| 08.10. | Oragenics partners Receptor.AI for brain health candidate portfolio | ||
| 08.10. | CDC amends Covid-19, chickenpox immunisation schedule amid vaccine controversy | ||
| 08.10. | Lilly's Omvoh benefit continues for four years in UC | ||
| 06.10. | Funds dry up for mRNA vaccines amid US political storm | ||
| 06.10. | FDA backs generics onshoring push with ANDA priority scheme | ||
| 06.10. | Rocket ditches blood disorder gene therapy in ongoing pipeline pivot | ||
| 06.10. | Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy | ||
| 06.10. | Jazz and Roche's Zepzelca-Tecentriq wins FDA ES-SCLC approval | ||
| 06.10. | McMaster University and MIT discover new antibiotic for IBD | ||
| 03.10. | FDA approves mifepristone generic as political abortion war rages on | ||
| 03.10. | Takeda walks away from cell therapy in priority U-turn | ||
| 03.10. | Amgen's Phase III data supports FDA label expansion of Repatha | ||
| 02.10. | FDA winds down operations amid government shutdown | ||
| 02.10. | FDA leaders are "acting political", says ex-agency chief counsel | ||
| 02.10. | Halozyme eyes microparticles in $900m Elektrofi acquisition | ||
| 02.10. | AbbVie breaks ground on $70m US biologics site amid Trump pressure | ||
| 01.10. | US Government shuts down over funding impasse | ||
| 01.10. | Pfizer shakes hands with White House on drug discounts under MFN programme | ||
| 01.10. | Klotho to acquire Turn Biotechnologies' assets | ||
| 01.10. | Star Therapeutics gains $125m Series D funds to develop pipeline |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .